Which company produces and develops Zotuximab/Veloximab?

Zolbetuximab (zolbetuximab) is an innovative monoclonal antibody developed and produced by Astellas Pharma, a well-known international pharmaceutical company. Astellas is a global pharmaceutical company headquartered in Tokyo, Japan, known for its continuous development of innovative medicines in the fields of oncology, immunology and rare diseases. It has been in the field of gastric cancer for many years and is committed to developing precise treatment options based on molecular markers. Zotuximab is one of the important results of this strategy.

Initially, the research and development of zotuximab was started by a German biopharmaceutical company. Later, Astellas acquired relevant R&D pipelines through strategic acquisitions and accelerated global multi-center clinical trials. Through cooperation with multiple research institutions and medical centers, the drug quickly entered the critical clinical stage and eventually received regulatory approval in some countries and regions. Astellas relies on its global R&D system and rich clinical development experience to enable zotuximab to quickly complete the transformation from laboratory research to clinical application.

Astellas Pharmaceuticals has extensive influence in the global anti-tumor drug market, and a number of its blockbuster products have been approved for marketing. Zotuximab, as its important layout in the field of digestive tract tumors, not only fills the gap in CLDN18.2 target drugs, but also further enriches the immunotherapy drug pipeline. The company's global promotion strategy gives zotuximab the opportunity to be quickly introduced into clinical practice in European, American and Asian markets, benefiting more patients.

In China, Astellas is also actively promoting the registration application for zotuximab. Combined with the large domestic gastric cancer patient population, it is expected that the drug will become a key product in tumor treatment. As accurate testing methods gradually become more popular, Astellas is expected to accelerate its accessibility in the Chinese market by cooperating with local companies and medical institutions.

Reference materials:https://www.astellas.com/en/news/29401